Illumina (ILMN) Gets Bernstein’s Market Perform Rating Amid NovaSeq X Recovery
Bernstein SocGen analyst Eve Burstein resumed coverage of Illumina (ILMN) with a Market Perform rating and $185 price target. She cited early-2025 China restrictions on Illumina instruments and inclusion on an Unreliable Entities List as weighing on revenue estimates, but said NovaSeq X and expanding clinical applications supported a recovery amid improving life-science funding and drug trial activity.
How this was made
The 30-second read
Why it matters
This is primarily a sell-side rating/PT update anchored to a specific operational recovery thesis and sector tailwinds; it may influence positioning but lacks new company-specific financial datapoints in the article.
Market read
Traders may use the $185 PT and recovery narrative to gauge sentiment, but the article doesn’t introduce new financial results or guidance.
What to watch
The piece doesn’t provide new quantitative evidence (e.g., updated revenue/guide, order data, or margins), so the PT may rely heavily on assumptions about funding and AI-driven tool demand.
Background
Bernstein SocGen analyst Eve Burstein resumed coverage after Illumina faced China import restrictions starting early 2025, then pointed to NovaSeq X and clinical application expansion as the recovery driver.
Ticker impact
Bernstein resumed coverage of Illumina with a Market Perform rating and a $185 price target, citing NovaSeq X recovery after China restrictions.
Near-term: modest upward bias if the market treats the PT/rating as credible; otherwise limited impact because it’s not a new fundamental print.
A rating/PT change can move sentiment, but the underlying facts described (China Unreliable Entities List, NovaSeq X recovery) are framed as context rather than newly disclosed data in this article.
Market effects
Reinforces a read-through that life-science tools/diagnostics demand may improve with drug approvals, trial starts, and better funding.
Highlights China-related import restrictions as a key swing factor for sequencing instrument revenue risk.
Supports the broader narrative that sequencing demand can rebound when product cycles (NovaSeq X) and funding conditions improve.
Counterpoint
NovaSeq X recovery may be slower or more cyclical than the analyst assumes; China restrictions could re-tighten and cap upside.
Key entities
- public_companyIllumina, Inc.
Subject of the article; receives a Market Perform rating and $185 price target tied to NovaSeq X recovery.
- analyst_firmBernstein SocGen (Eve Burstein)
Analyst who resumed coverage and set the rating/price target.
